Brief: Orchard Therapeutics Announces First Patient Dosed With Cryopreserved Formulation Of Otl-103 Gene Therapy For The Treatment Of Wiskott-Aldrich Syndrome
25/04/2019 14:06
April 25 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH
CRYOPRESERVED FORMULATION OF OTL-103 GENE THERAPY FOR THE
TREATMENT OF WISKOTT-ALDRICH SYNDROME
* ORCHARD THERAPEUTICS PLC - PROGRAM ON TRACK FOR MAA AND
BLA
REGULATORY SUBMISSIONS IN 2021
Source text for Eikon: ID:nGNX11Ty4l
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln